The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: GlobeNewswire
Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio (OTCQB: AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics (NASDAQ: FATE), Mesoblast (NASDAQ: MESO), Longeveron (NASDAQ: LGVN) Key Takeaways: • Avaí Bio (OTCQB: AVAI) has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the a-Klotho “longevity protein,” a GMP-compliant production milestone that transitions its anti-aging program from research into the manufacturing phase. • The global cell and gene therapy market is forecast to surge from $10.4 billion to more than $45 billion by 2035, with over 40 FDA-approved products and North America commanding more than half the global market[1]. • Avaí Bio’s dual-program approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, leveraging Austrianova’s Cell-in-a-Box® encapsulation technology backed by 50+ peer-reviewed publications. • Peer-reviewed research links a-Klotho to r
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswire
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
FATE
Earnings
- 11/13/25 - Beat
FATE
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 1/16/26 - Form 4
- FATE's page on the SEC website